Article

Evaluation of EULAR-RAID Score in Rheumatoid Arthritis Patients (Rainbow)

The main goal of this trial is to "evaluate the practical modalities and performance of the EULAR-RAID score in patients with rheumatoid arthritis who have been prescribed etanercept as part of usual medical practice."

Study Type: Interventional

Age/Gender Requirement: 18 years+ (male/female)

Sponsor: Wyeth

Researchers are looking for patients with RA who meet the 1987 ACR Revised Criteria for Rheumatoid Arthritis, can store injectable tests at 2-8 degrees Celsius, and are able and willing to "self-inject ETN or have a designee who can do so to participate in this phase IV clinical trial. The main goal is to "evaluate the practical modalities and performance of the [European League against Rheumatism Rheumatoid Arthritis Impact of Disease] EULAR-RAID score in patients with rheumatoid arthritis who have been prescribed etanercept as part of usual medical practice."

Click here to access this third-party website.

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
© 2024 MJH Life Sciences

All rights reserved.